Peter Casasanto
About Peter Casasanto
Peter Casasanto serves as the Chief BioPharma Officer at SOPHiA GENETICS in Lausanne, Switzerland, where he focuses on advancing novel therapies through strategic partnerships. With over 19 years of experience in the industry, he has held various leadership roles in business development and corporate strategy across several prominent organizations.
Current Role at SOPHiA GENETICS
Peter Casasanto serves as the Chief BioPharma Officer at SOPHiA GENETICS, a position he has held since 2022. Based in Lausanne, Vaud, Switzerland, he focuses on advancing novel therapies through strategic partnerships and business operations within the BioPharma Business Unit. His responsibilities include building a world-class business unit that leverages the SOPHiA DDM™ platform's data and analytics to drive key partnerships across the drug-development ecosystem. He employs a global, decentralized, and platform-agnostic approach to access high-quality real-world genomic, radiomic, and clinical data.
Professional Experience
Peter Casasanto has a diverse professional background in the biopharmaceutical industry. He previously worked at LabCorp Clinical Trials as Director of Business Development for Biomarkers & CDx from 2013 to 2014. He held various leadership roles at Tempus Labs, Inc., including Vice President of Life Sciences and Vice President of Corporate Development. His experience also includes serving as Executive Director of Corporate Development & Strategy Head at NeoGenomics Laboratories from 2016 to 2019, and as Associate Director of Business Development at PPD from 2009 to 2013. He started his career as a scientist at Merck in the Vaccines & Biologics group.
Education and Expertise
Peter Casasanto holds a Bachelor of Science in Molecular Biology and Genetics from the University of Maryland, which he earned from 1997 to 2002. He furthered his education with a Master of Science in Biomedical Chemistry from Jefferson Health, completed in 2005. He also obtained an MBA in Pharmaceutical Management from Drexel University's LeBow College of Business from 2005 to 2008. His expertise includes AI-enabled data-driven insights for novel biomarker discovery and improving clinical trial performance.
Leadership and Strategic Initiatives
In his various roles, Peter Casasanto has demonstrated leadership in business development, sales, client management, and growth strategy for BioPharma portfolios. He has led teams through mergers and acquisitions and has experience in developing commercial strategies for new corporate initiatives, particularly during his tenure at CellCarta. His work emphasizes utilizing proprietary algorithms for smart diagnostics and multimodal approaches to inform treatment decisions and therapy selection.
Career Timeline
Peter Casasanto's career spans over 19 years in the biopharmaceutical industry. He began as an Associate Scientist at Thomas Jefferson University from 2003 to 2005, then moved to Merck as a Research Immunologist from 2005 to 2008. He has held various positions at LabCorp Clinical Trials, PPD, NeoGenomics Laboratories, and Tempus Labs, culminating in his current role at SOPHiA GENETICS. His career reflects a strong focus on business development and strategic partnerships in the BioPharma sector.